The stock's fall snapped a two-day winning streak.

Hyderabad: The queue of global pharma giants wanting to make Hyderabad their new home for drug discovery and tech centres is ...

The UK's self-regulated system for disclosing payments from drug companies to healthcare professionals and organisations is failing to protect ...

New drug approved for treating chronic schizophrenia with fewer side effects. Could be beneficial for Black community.

Bristol Myers Squibb is doubling down on a partnership with Medidata, signing a multiyear agreement to continue using the ...

Licensing deals have risen in prominence in a restrained market environment. Is it desperation, or an important part of the ...

Highlights,Bristol-Myers Squibb beats quarterly earnings estimates.,Dividend increased, maintaining strong returns.,Insider ...

The FDA wrapped up 2024 with 50 new drug approvals, clearing a wave of long-awaited treatments. Meanwhile, Transcarent will ...

Topline data were announced from two phase 3 trials evaluating deucravacitinib in adults with active psoriatic arthritis.

Jefferies has recently raised Bristol-Myers Squibb Co (BMY) stock to Buy rating, as announced on December 16, 2024, according to Finviz. Earlier, on December 10, 2024, BofA Securities had resumed the ...

Researchers from the Broad Institute, Mass General, Stanford, and elsewhere are investigating why patients with South Asian ...

An initiative to improve care and standardize identification, assessment, referrals, and treatment for patients with HCM has been launched by the AHA.